EnginZyme secures 6.4 M€ investment to accelerate the development of its technology platform


Type of post: NEWS IN BRIEF.

EnginZyme has announced a Series A investment of 6.4 M€ led by Sofinnova Partners that will be used to accelerate the development of its technology platform and take its first internal production process to pilot.

Figure 1. EnginZyme secures 6.4 M€ investment to accelerate the development of its technology platform

EnginZyme, the cell-free synthetic biology company, was founded in Stockholm (Sweden) in 2014. Since its start, it has used its technology to provide R&D services to leading companies in multiple industries, such as pharma, food, chemicals and flavors & fragrances. The company seeks to solve one of the fundamental problems of our time: How to produce sustainable alternatives to plastics, nylons, rubbers, and the tons of other synthetics that are used on a daily basis, without compromising on cost-effectiveness. To achieve this, EnginZyme’s technology platform combines the breadth and power of nature (enzymatic cascades) with the efficiency of the chemical industry (packed bed reactors).

Dr. Engelmark Cassimjee (EnginZyme CEO) said: “It has long been recognized that if we could effectively access nature’s full palette of molecules, we could solve many of the world’s most pressing problems. There’s just so much more you can do with biological systems than with traditional catalysts and petroleum-based building blocks. But the key word here is ‘effectively’ – it needs to be as cheap and easy to scale as the chemical solutions we’ve used for more than a century now. We’re the first company to truly address that and by doing so we are building foundational technology for an entire future industry.”

Popular Posts

Biofuels from algae

Hidrotratamiento (HVO) – Conceptos, materias primas y especificaciones

Biorrefinerías de ácido levulínico

Etanol celulósico – Lo básico: Conceptos y materias primas

Gasificación de licor negro: El caso de Chemrec y la LTU